WP8:Clinical trial

Due to the obvious need in the transplant setting it would be unethical to delay administration to humans. Therefore, based on stringent pre-clinical safety and efficacy tests, we will seek approval to advance one anti-E2 and one anti-SRBI antibody into a proof of concept phase II trial for the evaluation of safety and efficacy in the target population. The objectives of this workpackage are to:

  • To gain human safety and early efficacy data for the lead monoclonal antibodies

  • To determine the neutralization phenotype of HCV present in patients recruited to clinical trial

  • To monitor the emergences of neutralization resistance in clinical trial patients